CARGO Therapeutics, Inc. (CRGX)
| Market Cap | 728.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -154.14M |
| Shares Out | 46.03M |
| EPS (ttm) | -4.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 206,616 |
| Open | 16.10 |
| Previous Close | 16.11 |
| Day's Range | 15.29 - 16.68 |
| 52-Week Range | 13.56 - 33.92 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 30.33 (+91.72%) |
| Earnings Date | Nov 12, 2024 |
About CRGX
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company’s lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, In... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for CRGX stock is "Strong Buy." The 12-month stock price forecast is $30.33, which is an increase of 91.72% from the latest price.
News
CARGO Therapeutics to Participate in Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc.
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) - - Completed $110 million private placement equity fina...
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
CARGO Therapeutics Announces $110.0 Million Private Placement Equity Financing
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND...
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel ( firi-cel) (CRG-022); Currently on-track for interim results exp...
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) – – Appoin...
CARGO Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March...
CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference
CARGO Therapeutics announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, MA.
CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell th...
CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell th...
U.S. IPO Weekly Recap: Reinsurance And CAR T Therapies Lead A 3 IPO Week
Three IPOs and two SPACs debuted this week, while the pipeline got a boost from a flurry of initial filings. Oncology biotech CARGO Therapeutics priced at the bottom of the range to raise $281 million...
Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold ...
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies. The IPO appears reasonabl...
Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $...
Cargo Therapeutics Begins $100 Million IPO Rollout
Cargo Therapeutics, Inc. has filed for a $100 million IPO to develop improved CAR T-cell therapy for large B-cell lymphoma. The company's lead candidate, CRG-022, is in Phase 2 trials for the treatmen...